1. Home
  2. IDYA vs CIVI Comparison

IDYA vs CIVI Comparison

Compare IDYA & CIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • CIVI
  • Stock Information
  • Founded
  • IDYA 2015
  • CIVI 1999
  • Country
  • IDYA United States
  • CIVI United States
  • Employees
  • IDYA N/A
  • CIVI N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • CIVI Oil & Gas Production
  • Sector
  • IDYA Health Care
  • CIVI Energy
  • Exchange
  • IDYA Nasdaq
  • CIVI Nasdaq
  • Market Cap
  • IDYA 2.2B
  • CIVI 2.6B
  • IPO Year
  • IDYA 2019
  • CIVI 2011
  • Fundamental
  • Price
  • IDYA $24.27
  • CIVI $33.30
  • Analyst Decision
  • IDYA Strong Buy
  • CIVI Buy
  • Analyst Count
  • IDYA 13
  • CIVI 11
  • Target Price
  • IDYA $51.36
  • CIVI $46.50
  • AVG Volume (30 Days)
  • IDYA 1.1M
  • CIVI 2.2M
  • Earning Date
  • IDYA 08-05-2025
  • CIVI 08-06-2025
  • Dividend Yield
  • IDYA N/A
  • CIVI 9.10%
  • EPS Growth
  • IDYA N/A
  • CIVI N/A
  • EPS
  • IDYA N/A
  • CIVI 7.93
  • Revenue
  • IDYA $7,000,000.00
  • CIVI $4,815,808,000.00
  • Revenue This Year
  • IDYA $101.44
  • CIVI N/A
  • Revenue Next Year
  • IDYA $263.37
  • CIVI N/A
  • P/E Ratio
  • IDYA N/A
  • CIVI $4.18
  • Revenue Growth
  • IDYA N/A
  • CIVI 0.23
  • 52 Week Low
  • IDYA $13.45
  • CIVI $22.79
  • 52 Week High
  • IDYA $40.74
  • CIVI $63.82
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 52.57
  • CIVI 59.21
  • Support Level
  • IDYA $22.09
  • CIVI $27.68
  • Resistance Level
  • IDYA $24.75
  • CIVI $33.20
  • Average True Range (ATR)
  • IDYA 1.25
  • CIVI 1.41
  • MACD
  • IDYA -0.13
  • CIVI 0.30
  • Stochastic Oscillator
  • IDYA 40.05
  • CIVI 89.31

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About CIVI Civitas Resources Inc.

Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.

Share on Social Networks: